Whitfield Advises Catalyst Pharmaceuticals on $4.1 Billion Sale to Angelini
Overview
Angelini Pharma agreed to buy Catalyst Pharmaceuticals for approximately $4.1 billion in equity value, according to the source announcement about the cash acquisition.
Offer terms
Catalyst shareholders were to receive $31.50 per share. The source also expresses the transaction value as approximately €3.5 billion.
Approvals and timing
Both boards reportedly approved the agreement unanimously, with completion anticipated during the third quarter of 2026.
Business and advisers
Catalyst develops and commercializes treatments for rare and difficult diseases. Graham Robinson and Chadé Severin are among the corporate advisers listed, alongside healthcare and competition specialists.
